FGFR2 and neoplasm: The addition of the antibody to chemotherapy (FOLFOX 6) was tested in a double-blind, placebo-controlled randomized phase II trial in unresectable locally advanced or metastatic gastric cancer in patients whose tumors showed FGFR2b overexpression by IHC or who had FGFR2 amplification by circulating tumor DNA (ctDNA) evaluation [4].